Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients

Cancer

Volumn 77, Issue 3, 1996, Pages 474-482

  Alo', Piero L ^a   Visca, Paolo ^a   Marci, Adele ^a   Mangoni, Antonella ^a   Botti, Claudio ^b   Di Tondo, Ugo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

breast carcinoma; c erbB 2; cathepsin D; estrogen receptor; FAS; progesterone receptor; prognosis

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; FATTY ACID SYNTHASE; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATHEPSIN D; DISEASE-FREE SURVIVAL; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS;

EID: 0030063936     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K     Document Type: Article

References (48)

1. Gasparini G, Pozza F, Harris AC. Evaluating the potential useful and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-19.
2. Osborne CK. Prognostic factors for breast cancer, have they met their promise? J Clin Oncol 1992;10:679-82.
3. Spiessl B, editor. International Union Against Cancer. TNM-Atlas: illustrated guide to TNM/pTNM-classification of malignant tumors. 3rd edition. Berlin: Springer-Verlag, 1989: 174-83.
4. Hutter RV. The influence of pathologic factors on breast cancer management. Cancer 1980;46:(Suppl 4)961-76.
5. Kuhajda FP, Katumuluwa AI, Pasternack GR. Expression of haptoglobin related protein and its potential role as a tumor antigen. Proc Natl Acad Sci USA 1989;86:1188-92.
6. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential target for antineoplastic therapy Proc Natl Acad Sci USA 1994;91: 6379-83.
7. Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobin-related protein (Hpr). Epitopes in breast cancer as a predictor of recurrence of disease. N Engl J Med 1989;321:636-41.
8. Shurbaji MS, Pasternack GR, Kuhajda FP. Expression of aptoglobin related protein in primary and metastatic breast cancer. Am J Clin Path 1991;96(2):238-42.
9. Rosen PP, Oberman HA. Tumors of the mammary gland. 3rd series. Washington: AFIP, 1993:157-243.
10. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1049 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-77.
11. Page DL, Anderson TS. Vessel invasion. In: Page DL, Anderson TL, editors. Diagnostic histopathology of the breast. Edinburgh, UK: Churchill Livingstone, 1987:283-4.
12. Hsu SM, Raine L, Fanger H. The use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
13. Kuhajda FP, Eggleston JC. Pregnancy-associated plasma protein A and extensive necrosis: clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma. Lab Invest 1985;53:101-7.
14. Tandon AK, Clark GM, Chamnes GC, Chirgwin JM, Mc Guire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990;322:297-302.
15. Castiglioni T, Merino MJ, Elsner B, Tamara T, Bonnie F, Michael R, et al. Immunohistochemical analysis of cathepsin D, B and L in human breast cancer. Hum Pathol 1994;25(9):857-62.
16. Singleton TP, Gloria A, Niehans GA, Gu F, Litz C, Haggy K, et al. Detection of c-erbB-2 activation in paraffin embedded tissue by immunohistochemistry. Hum Pathol 1992;23(10): 1141-50.
17. Wright C, Angus B, Nicholson S, Sainsbury Jr, Cairns J, Gullic WJ, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90.
18. Helin HJ, Helle MJ, Helin ML, Isola JJ. Immunocytochemical detection of estrogen and progesterone receptors in 124 human breast cancers. Am J Clin Pathol 1988;89:137-42.
19. Brennet S. Log logistic regression models for survival data. Appl Stat 1983;32:165-71.
20. Cox DR. Regression model and life-tables. J R Stat Soc (B) 1972;34:187-20.
21. Dixon WJ, editor. BMDP Statistical Software. Berkeley: University of California Press 1985:143-208,519-37,555-94.
22. Corrigan C, Martin AW, Lear SC, Kuhns G, Kuhajda FP, Pasternack GR. Prognostic value of the immunohistochemical demonstration of Haptoglobin-related protein in breast cancer. [abstract]. Am J Clin Pathol 1991:406.
23. Arnould L, Riedenger JM, Lizard-Nacol S, Collin F, Magnin E, Cuisenier J, et al. Histological data in node-negative breast cancers: correlation with new biological markers [abstract]. Pathol Res Pract 1993;189(6-7):639.
24. Lee AK, De Lellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990;8:1457-65.
25. Clemente CG, Boracchi P, Andreola S, Del Vecchio M, Veronesi P, Rilke FO. Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 1992;69:1396-1403.
26. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Della Palma P, Caffo O, et al. Tumor microvessel density, P53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
27. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, et al. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. J Cancer Res Clin Oncol 1989;49: 6008-1.
28. Brouillet JP, Theillet C, Maudelonde T, Defrenne A, Simony-Lafontaine J, Sertour J, et al. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erbB-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer 1990;26:437-41.
29. Westley B, Rochefort H. A secreted glicoprotein induced by estrogen in human breast cancer lines. Cell 1980;20:352-62.
30. Cowman WK, Angus B, Henry J, Corbett IP, Reid WA, Horne CHW. Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening. Br J Cancer 1991;64:780-4.
31. Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K, Osborn M. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry: no correlation with survival at 5 years. Am J Pathol 1992;141:1003-12.
32. Kandalaft P, Chang K, Ahn C. Immunohistochemical analysis of cathepsin D in breast cancer; is it prognostically significant? [Abstract 75] Ann M US and Can Acad Path Atlanta 1992;3:14-20.
33. Armas OA, Gerald WL, Lesser ML, Arroyo CD, Norton L, Rosen PP. Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am J Surg Pathol 1994;18(2):158-66.
34. Cardiff RD. Cathepsin D and breast cancer useful? Hum Pathol 1994;25:847-8.
35. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomial location with neu-oncogene. Science 1985;230:1132-4.
36. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. C-erbB-2 is a potent oncogene when over-expressed in NIH/3T3 cells. Science 1987;237:178-82.
37. Maggioni M, Roncalli M, Viale G, Comi A, Alfano RM, Graziani D, et al. C-erbB-2 amplification and overexpression in breast carcinoma. [Abstract 748] Pathol Res Pract 1993;189:6-7.
38. Bacus SS, Ruby SG, Weinberg DS, Chin D, Ortiz R, Bacus JW. HER-2/oncogene expression and proliferation in breast cancers. Am J Pathol 1990;137:103-11.
39. McCann A, Derwan PA, Johnston PA, Gullick WJ, Carney DN. C-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990;65:88-92.
40. Wright C, Angus B, Nicholson S, Sainsburgy RC, Cairns J, Gullick WJ, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-90.
41. Anderson TJ. C-erbB-2 oncogene in breast cancer: the right target or a decoy? Hum Pathol 1992;23:971-3.
42. Gasparini G, Gullick WJ, Bevilacqua P, J. Richard C Sansbury, Meli S, et al. Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992;10:686-95.
43. Cooke T, Shields R, George D, Maynard P, Griffiths K. Oestrogen receptors and prognosis in early breast cancer. Lancet 1979;1:995-7.
44. Sahin AA, Ro JY, El-Naggar AK, Wilson PL, Teague K, Blick M, et al. Tumor proliferating fraction in solid malignant neoplasm. Am J Clin Pathol 1991;96:512-9.
45. Isola JJ, Helin HJ, Helle MJ, Kallioniemi O. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki 67 immunohistochemical study, DNA, flow cytometric analysis and mitotic count. Cancer 1990;65:1180-4.
46. Chalbos D, Joyeux C, Escot T, Galter F, Rochefort H. Progestin-induced fatty acid synthetase in breast cancer. Ann NY Acad Sci 1990;595:67-73.
47. Shurbaji MS, Kuhajda FP, Pasternack GR, Thurmond TS. Expression of Oncoantigen 519 (OA-519) in prostatic cancer is a potential prognostic indicator. Am J Clin Pathol 1992;97:686-91.
48. Petta S, Tonelli VH, Carbone A, Alo' P, Graziano P, Di Tondo U. Expression of Oncoantigen (OA) 519 in prostatic carcinomas Preliminary results [Abstract 374]. XI Congress of EAU, Berlin, July 10, 1994.